In the Swiss government there is a will to limit the number of doctors themselves, because with new bilateral agreements with the European Union, there is what we call the "free flow of persons"; that our borders are open to immigration. And as the Swiss doctors are better paid than others, we could have a huge increase of immigration of doctors, more than we need. So we decided to limit the numbers of doctors coming into Switzerland. It is not a very intelligent system, but it is the best one that we have found to limit immigration of doctors.

In the Swiss government there is a will to limit the number of doctors themselves, because with new bilateral agreements with the European Union, there is what we call the "free flow of persons"; that our borders are open to immigration. And as the Swiss doctors are better paid than others, we could have a huge increase of immigration of doctors, more than we need. So we decided to limit the numbers of doctors coming into Switzerland. It is not a very intelligent system, but it is the best one that we have found to limit immigration of doctors.

If you look at figures, we have a good supply of doctors in Switzerland. They always say that in the future we shall have a lack of home doctors, family doctors. I'm not sure of that, but we have a problem of formation. Every year there [are] about 1,000 students beginning medical studies, and at the end of the formation there are only 600 young people getting the diploma. It means that about 40 percent of the students fail during the studies, although there is a selection at the beginning. Forty percent is too much as failure, so probably there is a problem in the formation, education.

If you look at the expenses of a great pharmaceutical company, they pay between about 10 to 15 percent of their expenses for research, but they use 30 to 40 percent of their incomes for marketing and promotion. It is not completely wrong that they spend so much, but it is not correct to say that there is a direct connection between the price of drugs and the cost of research. It could be more between the cost of marketing and the cost of the drugs.